Aytu Biopharma (AYTU) grants director 10,000 restricted shares vesting 2027

Rhea-AI Filing Summary

JAIN ABHINAV reported acquisition or exercise transactions in this Form 4 filing.

AYTU Biopharma reported that director Abhinav Jain received a grant of 10,000 shares of Common Stock as restricted stock on July 28, 2026, at a stated price of $0.0000 per share. These shares vest on July 28, 2027. After this award, Jain directly holds 29,500 shares of AYTU common stock.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider JAIN ABHINAV

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	10,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 29,500 shares (Direct)

Footnotes (1)

1. F1. Grant of restricted stock, which vest on July 28, 2027.

Key Figures

Restricted stock granted: 10000.0000 shares Price per share: 0.0000 Shares held after grant: 29500.0000 shares +1 more

4 metrics

Restricted stock granted 10000.0000 shares Grant of common stock to director on July 28, 2026

Price per share 0.0000 Stated per-share value for the restricted stock grant

Shares held after grant 29500.0000 shares Total direct AYTU common shares held by Abhinav Jain after transaction

Vesting date July 28, 2027 Date when the 10,000 restricted shares are scheduled to vest

Key Terms

restricted stock, vest, grant, award, or other acquisition

3 terms

restricted stock financial

"Grant of restricted stock, which vest on July 28, 2027."

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

vest financial

"Grant of restricted stock, which vest on July 28, 2027."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

grant, award, or other acquisition regulatory

"transaction code description: Grant, award, or other acquisition"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/30/2026 - 04:32 PM Accepted by SEC EDGAR 07/30/2026 - 04:31 PM Learn about SEC filing dates

FAQ

What insider transaction did AYTU director Abhinav Jain report on this Form 4 for AYTU?

Abhinav Jain reported receiving a grant of 10,000 shares of AYTU common stock as restricted stock on July 28, 2026. The award was recorded at a $0.0000 per-share price, reflecting an equity compensation grant rather than an open-market purchase.

How many AYTU shares does Abhinav Jain hold after this reported grant on the Form 4 for AYTU?

Following the reported grant, Abhinav Jain directly holds 29,500 shares of AYTU common stock. This total includes the newly granted 10,000 restricted shares, which are subject to vesting conditions through July 28, 2027, as described in the transaction footnote.

When do the 10,000 restricted AYTU shares granted to Abhinav Jain vest?

The 10,000 restricted shares of AYTU common stock granted to Abhinav Jain vest on July 28, 2027. Until that vesting date, the shares are subject to the company’s restricted stock conditions, as indicated in the Form 4 footnote for this transaction.

Was the AYTU Form 4 transaction for Abhinav Jain an open-market buy or a compensation grant?

The Form 4 describes the transaction as a grant, award, or other acquisition of common stock, not an open-market purchase. The per-share value is listed as $0.0000, consistent with equity compensation rather than a cash-funded buy in the market.

What type of security did Abhinav Jain acquire in this AYTU Form 4 filing?

Abhinav Jain acquired Common Stock of AYTU in the form of restricted stock. The filing notes a grant of 10,000 shares that vest on July 28, 2027, with the holdings characterized as direct ownership after the transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JAIN ABHINAV

(Last) (First) (Middle)

C/O AYTU BIOPHARMA, INC.

7900 EAST UNION AVENUE, SUITE 920

(Street)

DENVER COLORADO 80237

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AYTU BIOPHARMA, INC [ AYTU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2026		A		10,000(1)	A	$0	29,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock, which vest on July 28, 2027.

	/s/ Ryan J. Selhorn as attorney-in-fact for Abhinav Jain	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)